Jaguar Health Explores Strategic Alternatives for Intestinal Failure Program

Jaguar Health, Inc. has announced an exploration of strategic alternatives aimed at maximizing shareholder value in alignment with their anticipated New Drug Application (NDA) for a crofelemer-based drug targeting rare intestinal failure diseases. Potential options being considered include mergers, acquisitions, and partnerships with both biotech and non-biotech firms.

CEO Lisa Conte emphasizes the company's commitment to its crofelemer development program, aiming to provide solutions for patients suffering from intestinal failure (IF). This condition requires long-term nutritional support with significant complications. The estimated global market for treatments related to this condition, such as microvillus inclusion disease, is projected to rise significantly.

Crofelemer has shown promising results, reducing parenteral support in trials. A forthcoming abstract on these findings will be presented during the ESPGHAN Annual Meeting.